Health & Science

Home Health & Science

Biden Cancer Diagnosis Spurs White House Coverup Accusations

Photo via Gage Skidmore Flickr

The news of former President Joe Biden’s cancer diagnosis has sent shockwaves across America.

Biden’s team announced Sunday that he’d been diagnosed with an aggressive form of prostate cancer that had already metastasized to the bone, adding his family would examine suitable treatment for the “management” of the disease.

The shocking news comes amid heightened scrutiny surrounding the Bidens potential coverup of former President Biden’s mental and physical decline while in office.

On Monday, Rep. Ronny Jackson (R-TX) accused the Biden White House of a “political cover up” and lashed out at Biden’s then-White House doctor, though not by name, and accused the physician of having failed to deliver “world class care” to Biden and engaging in a “cover up.”

President Donald Trump posted a message to his Truth Social app on Sunday from himself and First Lady Melania Trump expressing their sympathy and well-wishes for Biden, after it was announced that the former president is battling very serious prostate cancer.

Trump Jr. likewise initially offered an expression of sympathy, by way of reposting a message on his account at X.

Sharing a screenshot that included the message “Politics aside, we wish [President Biden] a speedy recover,” Trump Jr. commented “Agreed 100%.”

In another post three hours later which also included a screenshot, Trump Jr. had a more critical take on the tragic news.

His screenshot showed a message on the nature of Biden’s particular cancer, and calling into question the timeline of when Democrats, or at least the White House, knew about it.

“What I want to know is how did Dr. Jill Biden miss stage five metastatic cancer or is this yet another coverup???” he said, with a sarcastic jab at former First Lady Jill Biden.

The hosts of Fox & Friends were in disbelief Monday morning at Joe Biden’s advanced cancer diagnosis despite the “fantastic medical care” that he receives as a former president.

“These are the types of things you look for when you get older,” Kilmeade added. “And very curious to see and somewhat discouraging to think someone could have this type of medical attention and have this get to this point.”

Co-host Charles Hurt added: “Especially because it’s a fairly advanced form so much so that it has metastasized to a bone. And you would think that would give you a lot more time to catch it.”

Later in the show, the curvy couch welcomed Fox News medical expert Dr. Marc Siegel, who echoed their surprise.

“Really, really surprising that it’s this advanced at the time of diagnosis,” he said. “Now, you can miss prostate cancer but most of the time regular screening picks it up. A sitting president I would expect to have advanced screening should not be subject to debate what kind of screening.”

Media Buzzes Over Trump’s Appearance – But Health Remains Strong, White House Says

Gage Skidmore from Surprise, AZ, United States of America, CC BY-SA 2.0 , via Wikimedia Commons

President Donald Trump set off another round of social media speculation Friday after cameras caught what looked like copious amounts of makeup on his hand during public appearances in Washington.

A patch of foundation, slightly lighter than his skin tone, was visible while he toured an exhibit at The People’s House museum. Later that day, during the World Cup 2026 draw event at The Kennedy Center, Trump kept one hand over the other while addressing the crowd — a move that didn’t go unnoticed by outlets like The Daily Beast, which pointed out the recurring appearance of cosmetic cover.

This isn’t the first time similar images have made the rounds. Observers cited previous instances following Trump’s meetings with French President Emmanuel Macron in February, European Commission President Ursula von der Leyen in July, and U.K. Prime Minister Keir Starmer.

Asked about the chatter, White House Press Secretary Karoline Leavitt brushed aside the tabloid-style coverage.

“President Trump is a man of the people, and he meets more Americans and shakes more hands on a daily basis than any other president in history,” Leavitt told The Independent Saturday. “His commitment is unwavering, and he proves that every single day.”

The renewed scrutiny follows last month’s stir over photos showing discoloration and swelling in Trump’s legs during a FIFA Club World Cup appearance. The White House later confirmed the president has chronic venous insufficiency — a common circulatory condition in which blood pools in the veins due to weakened valves.

According to the Cleveland Clinic, the condition can lead to discomfort but is manageable. Leavitt said Trump isn’t in pain and hasn’t required treatment or changes to his daily routine.

In April, White House physician Capt. Sean Barbabella declared the president in “excellent cognitive and physical health” after his annual checkup. He attributed bruising on Trump’s hands to aspirin therapy, a standard precaution for heart health.

Leavitt emphasized that the president’s physician remains available to answer any medical questions and insisted, “There is nothing to hide.”

READ NEXT: Former Trump Ally Issues Fiery Response To Shock Report

Letitia James Sues Federal Government

The White House, Public domain, via Wikimedia Commons

New York Attorney General Letitia James (D) sued the federal government Tuesday, arguing that a new Department of Health and Human Services (HHS) policy unlawfully ties major federal funding streams to compliance with the Trump administration’s new restrictions on gender-related medical care for minors.

The lawsuit challenges an HHS policy that, according to the attorneys general, conditions billions of dollars in health, education and research funding on compliance with a presidential executive order addressing sex and gender-related treatments.

Fox News reports:

“The federal government is trying to force states to choose between their values and the vital funding their residents depend on,” James said in a statement. “This policy threatens healthcare for families, life-saving research, and education programs that help young people thrive in favor of denying the dignity and existence of transgender people.”

The dispute stems from President Donald Trump’s January 2025 executive order directing HHS to take steps to curb what the administration calls “chemical and surgical mutilation” of children. President Trump has made limits on transgender-related medical care for minors a central part of his second-term domestic agenda.

NYC Public Advocate Tish James via Wikimedia Commons

Last month, HHS announced a sweeping package of proposed regulatory actions aimed at ending what it described as “sex-rejecting procedures” for minors. In guidance accompanying the announcement, the department warned that doctors and health systems could be excluded from federal health programs — including Medicare and Medicaid — if they provide treatments such as puberty blockers, hormone therapy, and gender surgeries to minors.

James’ lawsuit argues that the federal government is using funding leverage to pressure states, hospitals, universities, and other institutions to change policies on transgender care.

The attorneys general also claim HHS lacks legal authority to impose the conditions and is attempting to rewrite federal law through executive action. They argue the policy is vague and fails to spell out what recipients must do to remain compliant, creating uncertainty for states and institutions that rely on federal dollars.

Failure to comply with the policy could lead to termination of grants, repayment of funds already spent, or potential civil or criminal penalties, according to the complaint.

The lawsuit asks a federal court to declare the policy unlawful and block HHS from enforcing it, allowing states and institutions to continue receiving federal funding without changing existing policies.

The legal fight also adds to the long-running political and courtroom clash between Trump and James. James has positioned herself as one of the country’s most aggressive state-level opponents of Trump, repeatedly using New York’s legal powers to pursue high-profile cases involving his businesses and allies. Trump has frequently accused James of pursuing politically motivated investigations.

Trump officials have defended the executive order as a child-protection measure and a pushback against what they say is ideological medicine being imposed through federal agencies and school systems.

The case is expected to intensify a national debate already playing out in Congress and state legislatures, where Republican-led states have moved to restrict or ban gender-related treatments for minors, while Democrat-led states have expanded protections and access.

READ NEXT: Sen. Marsha Blackburn Pushes To Make Fraud A Deportable Offense

Noem Hospitalized After Allergic Reaction; Biohazard Lab Visit Under Scrutiny

1
Photo via Pixabay images

On the evening of Tuesday, June 17, 2025, Homeland Security Secretary Kristi Noem was rushed by ambulance to a Washington, D.C. hospital after suffering what officials described as an allergic reaction. According to a statement from the Department of Homeland Security (DHS), Noem was treated “out of an abundance of caution” and remains in stable condition.

The medical emergency drew swift attention — not only because of Noem’s high-profile cabinet role, but also due to the timing. Just one day earlier, she had visited the Integrated Research Facility at Fort Detrick, Maryland, a high-security federal lab that handles some of the world’s most dangerous pathogens, including Ebola and SARS-CoV-2. She was accompanied on the tour by Health and Human Services Secretary Robert F. Kennedy Jr. and Senator Rand Paul (R-Ky.).

The Fort Detrick facility has been under scrutiny in recent months. In April, it was temporarily shut down following safety concerns involving possible tampering with personal protective equipment. Though the lab has since resumed operations, the incident left lingering questions about oversight and internal protocols.

While the proximity of Noem’s hospital visit to her tour of the lab has sparked speculation, DHS downplayed any connection. Officials stressed there is no indication the allergic reaction had anything to do with the biohazard site, and current evidence points to coincidence, not causation.

Still, the lack of detail surrounding Noem’s condition — and the decision to visit to a facility recently flagged for a safety lapse — has fueled speculation. Noem has not issued a public statement since the incident, though an official told the Associated Press that the secretary is “alert and recovering.”

Security around the hospital was visibly heightened following Noem’s arrival, with multiple eyewitnesses reporting Secret Service personnel stationed at emergency entrances and perimeter points.

As of now, Noem remains under medical supervision, and DHS has indicated she will resume duties once cleared by her doctors. The department has not disclosed whether additional tests are being conducted to rule out environmental or chemical triggers.

What We Know — and Don’t

The facts are straightforward, even if the full picture isn’t: Secretary Noem had an acute medical event. She had just visited a facility known for housing lethal biological agents. There’s no official link between the two events. But in an era when institutional trust runs thin and information gaps invite conspiracy theories, the sequence of events is likely to keep this story alive longer than a typical health scare.

For now, DHS says Noem is recovering and expected to make a full recovery. But until more details emerge — from medical professionals or Noem herself — the story will likely remain a focus of intense public interest.

READ NEXT: Musk Confronts Key Ally — Forces Bombshell Admission

Trump Urged To Intervene After Vance Relative Reportedly Denied Organ Transplant Over Covid Vax

3

President Donald Trump is facing pressure to use his executive power to block hospitals from denying organ transplants for people not vaccinated against COVID-19 after reports emerged that Vice President JD Vance’s 12-year-old relative was reportedly denied a heart transplant over her COVID-19 vaccination status

In a letter to President Trump, Rep. Michael Rulli (R-Ohio) alongside Rep. Erin Houchin (R-Ind.) called on Trump to take action. Rep. Rulli said he was partially moved to act after hearing about Vance’s relative.

The letter, signed by Rulli, Houchin and five other House Republicans, cited Trump’s executive orders ending COVID-19 vaccine mandates in schools and reinstating military service members who were discharged for not getting the vaccine. (RELATED: Trump Reinstates Service Members Discharged Over COVID-19 Vaccine In Executive Order Flurry)

“Over the past week, it has come to light that multiple desperate Americans have been denied life-saving organ transplants due to their COVID-19 vaccination status,” the letter said. “This outrageous denial of care has affected some of our most vulnerable citizens – including a child from Indiana and a veteran from Ohio.”

Houchin told Fox News, “Patients – especially children – should never be turned away from care due to government-imposed mandates. This effort urges President Trump to take action to ensure no hospital or transplant center can discriminate against patients based on their decision to decline the COVID-19 vaccine.”

“President Trump has done such a great job recently on executive orders,” Rulli told Fox News Digital in an interview. “And I am asking President Trump if he sees this, to please do an executive order… because you could save someone’s life today.”

“The timing is everything. If we don’t get this done, people’s lives could be at risk.”

Read:

The girl’s mother, Jeneen Deal, told the Daily Mail that giving her daughter the vaccine would violate the family’s religious beliefs.

Vance said in comments to the Daily Mail that he would try to help.

“I guess it’s been circulating on social media, but I was made aware of a couple days ago, and we’re trying to dig in and trying to help, obviously, as much as possible,” he said.

Senate Votes To Confirm Health and Human Services Secretary

3
Photo via Gage Skidmore Flickr

The U.S. Senate has confirmed Robert F. Kennedy Jr. as the next Secretary of Health and Human Services (HHS) following weeks of debate over his nomination.

Once again, Sen. Mitch McConnell (R-Ky.) stood alone as the only Republican to vote against President Trump’s nominee. McConnell opposed Tulsi Gabbard’s nomination as director of national intelligence (DNI).

The confirmation process was marked by intense scrutiny of Kennedy’s record and policy positions. The Senate Finance Committee advanced his nomination last Tuesday with a narrow 14-13 vote.

Senator Bill Cassidy (R-La.), a physician and key swing vote, played a decisive role in moving Kennedy’s nomination forward. Cassidy, who has represented Louisiana in the Senate since 2014, broke with some in his party to support the nominee.

The full Senate advanced Kennedy’s nomination on Wednesday following a successful cloture vote of 53 to 47.

During his confirmation process, Kennedy worked to distance himself from past remarks that raised doubts about vaccine safety.

Despite the controversy, he managed to secure enough backing from Republicans to push his nomination forward.

As head of HHS, Kennedy will oversee federal health policy, including responses to public health crises, health care regulations and medical research funding. His tenure is expected to bring significant policy debates, particularly regarding vaccine policy, regulatory oversight and public health initiatives.

With Kennedy now confirmed, all eyes will be on how he navigates key health policy challenges in the months ahead.

This is a breaking news story. Please check back for updates.

Republican Congressman Hospitalized In Car Accident

Photo via Pixabay images

Rep. Jim Baird (R-Ind.) has reportedly been hospitalized after a car accident.

Baird is responsive and in stable condition, Fox News reported.

Baird’s hospitalization came moments after it was announced House GOP Rep. Doug LaMalfa (R-Calif.) had suddenly passed away at age 65.

LaMalfa represented part of California and was chair of the Congressional Western Caucus.

“Jacquie and I are devastated about the sudden loss of our friend, Congressman Doug LaMalfa. Doug was a loving father and husband, and staunch advocate for his constituents and rural America. Our prayers are with Doug’s wife, Jill, and their children,” Emmer said.

His death brings House Republicans’ majority down to 218 to 213. 

Trump Breaks Silence On Biden’s Cancer Diagnosis

0
The White House, Public domain, via Wikimedia Commons

President Donald Trump expressed sympathy for former President Joe Biden following Sunday’s surprise announcement of Biden’s aggressive prostate cancer diagnosis. In a Truth Social post, Trump stated:

“Melania and I are saddened to hear about Joe Biden’s recent medical diagnosis. We extend our warmest and best wishes to Jill and the family, and we wish Joe a fast and successful recovery.”

Biden, 82, was diagnosed with a high-grade, hormone-sensitive prostate cancer that has metastasized to the bone. Biden and his family are currently reviewing treatment plans with his medical team.

Trump’s message marks a notable moment of bipartisan compassion amid ongoing political tensions.

In his first public statement following the diagnosis, Biden expressed gratitude for the outpouring of support, saying:

“Cancer touches us all. Like so many of you, Jill and I have learned that we are the strongest in broken places.”

The announcement has prompted a wave of bipartisan support, with messages of encouragement from various political figures, including Kamala Harris and Barack Obama.

However, not all reactions have been as supportive. Donald Trump Jr. initially shared a message wishing President Biden a speedy recovery but later posted a controversial comment questioning how Dr. Jill Biden could have missed signs of advanced cancer, suggesting a possible cover-up. “What I want to know is how did Dr. Jill Biden miss stage five metastatic cancer—or is this yet another cover-up???” Trump Jr. wrote on X (formerly Twitter). His post was widely criticized for its accusatory tone and for failing to note that Jill Biden holds a doctorate in education, not medicine.

According to Newsweek‘s reporting, the cancer presumably developed rapidly, despite Biden’s routine screenings intended to detect it early:

A professor of oncology told Newsweek that Joe Biden would have been tested for prostate cancer while in office and it is likely his cancer developed rapidly.

Gage Skidmore, CC BY-SA 2.0 , via Wikimedia Commons

Biden’s age and health were dominant concerns among voters during his time as president. The 82-year-old dismissed concerns about his mental acuity, but ultimately dropped his bid for a second term following a disastrous debate performance in June last year. He was replaced as the Democratic nominee by then-Vice President Kamala Harris, who lost to President Donald Trump.

Questions have been raised about the Biden administration and campaign’s transparency about Biden’s age and cognitive ability. An upcoming book alleges White House aides covered up Biden’s physical and mental decline. However, there is no current indication publicly available that Biden was diagnosed with prostate cancer during his tenure as president.

Biden’s office said the former president was diagnosed with prostate cancer on Friday, with the cancer cells having spread to the bone.

Supreme Court Greenlights Trump NIH Cuts Targeting DEI, COVID Research

The U.S. Supreme Court on Thursday cleared the way for the Trump administration to move forward with nearly $800 million in cuts to National Institutes of Health grants.

The decision allows the administration to withhold funds that had been frozen by a lower court — grants largely tied to diversity, equity, and inclusion (DEI) initiatives, as well as studies focused on minority health, LGBTQ+ issues, vaccine hesitancy, COVID-19, and similar public health topics.

A federal trial court in Massachusetts had previously ruled in June that many of the cuts were “arbitrary and discriminatory,” ordering the temporary restoration of those grants.

But the Supreme Court, acting through its emergency — or so-called “shadow” — docket, overrode that ruling in a narrow 5–4 decision.

Chief Justice John Roberts sided with the liberal bloc in dissent. Justice Ketanji Brown Jackson issued a sharply worded dissent of her own, criticizing the court’s reliance on the emergency process and the brevity of the majority’s explanation.

As SCOTUSBlog reports, the court — also by a 5–4 margin — left in place another part of the lower court’s ruling affecting internal NIH guidance documents outlining the agency’s policy priorities:

Justice Amy Coney Barrett provided the key vote on each issue. She joined Justices Clarence Thomas, Samuel Alito, Neil Gorsuch, and Brett Kavanaugh in voting to allow NIH to terminate the grants, but she joined Chief Justice John Roberts and Justices Sonia Sotomayor, Elena Kagan, and Ketanji Brown Jackson in voting to leave the lower court’s ruling on the guidance documents in place.

Jackson had sharp words for her colleagues, describing the ruling as “Calvinball jurisprudence” – a reference to the Calvin and Hobbes cartoon – “with a twist. Calvinball has only one rule: There are no fixed rules. We seem to have two: that one, and this Administration always wins.”

NIH ended hundreds of grants it linked to DEI-related studies in response to a series of executive orders issued by President Donald Trump after his inauguration in January. The first order, titled “Ending Radical and Wasteful Government DEI Programs and Preferencing,” instructed the director of the Office of Management and Budget, assisted by the attorney general and the director of the Office of Personnel Management, to work to end “discriminatory programs, including illegal DEI” programs in the federal government. It was followed by two other executive orders, titled “Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government” and “Ending Illegal Discrimination and Restoring Merit-Based Opportunity.”

Two separate groups of plaintiffs went to federal court in Massachusetts to challenge the termination of the grants. One group is made up of 16 states whose public universities receive funding from NIH, while the other consists of the American Public Health Association, individual researchers, a union, and a reproductive health advocacy group. They contended that the termination of the grants violated both the Constitution and the Administrative Procedure Act, the federal law governing administrative agencies.

The administration argues the research in question lacks scientific rigor and was driven more by ideology than merit. Officials also say the cuts are consistent with their broader push to eliminate DEI-related spending across federal agencies.

Democrat-led states and advocacy groups claim the funding loss could have “incalculable” consequences for underserved communities.

This case fits a broader pattern: The court has recently upheld rollbacks on DEI-based spending in areas like teacher training. Critics say the use of the emergency docket limits public transparency and bypasses full hearings. Supporters say it’s a legitimate tool to keep activist courts in check.

Legal challenges are still moving through the lower courts.

In the meantime, universities, NIH personnel, and left-leaning advocacy groups are mobilizing in protest, warning of long-term damage to public health research and institutional equity efforts.

READ NEXT: Police Swarm Former Trump Ally’s Mansion

Trump Signs Executive Order To Tie US Drug Prices To Global Lows

0

On Monday morning, President Donald Trump signed a sweeping executive order aimed at dramatically lowering prescription drug prices in the United States. At the center of the order is a “most favored nation” (MFN) pricing policy, which mandates that the U.S. pay no more for medications than the lowest price paid by any other country. Trump claims the initiative could cut drug prices by 30% to 80%, potentially saving American taxpayers trillions of dollars.

The MFN policy revives a proposal from Trump’s first term and targets the longstanding disparity in drug costs between the U.S. and other nations. The order also directs the Department of Health and Human Services to begin broad drug price negotiations, while introducing measures to combat anti-competitive practices, expand drug imports, and scrutinize the role of pharmacy benefit managers (PBMs).

The New York Post reports:

“What’s been happening is, we’ve been subsidizing other countries throughout the world,” Trump explained at a White House signing ceremony, calling Monday’s action one of his “most important orders.”

“Some prescription drug and pharmaceutical prices will be reduced almost immediately by 50 to 80 to 90%, he added. “Big Pharma will either abide by this principle voluntarily or we’ll use the power of the federal government to ensure that we are paying the same price.”

The policy is a revival of Trump’s signature “most favored nation” drive from his first term, with a new push to get foreign countries to take on more of the research and development (R&D) costs that experts say America has disproportionately shouldered.

“Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before,” the president previously promised on Truth Social Sunday. “The United States will save TRILLIONS OF DOLLARS.”

The announcement triggered immediate market reaction, with shares of pharmaceutical giants like AstraZeneca and GSK seeing declines. Industry leaders have warned the policy could stifle innovation and competition, arguing it may disincentivize research and development.

Although the Biden administration previously took steps to lower drug prices through the Inflation Reduction Act, Trump’s executive order takes a more aggressive approach by linking U.S. prices directly to global lows.

However, the new policy is expected to face significant legal and logistical hurdles, particularly due to the complexity of the U.S. drug pricing system and the opaque nature of international pricing mechanisms.